- Home
- KBR vs GRFS Comparison
KBR vs GRFS Comparison
Compare KBR & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KBR | GRFS |
|---|---|---|
| Founded | 1901 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | 2006 | 2008 |
Fundamental Metrics
Financial Performance| Metric | KBR | GRFS |
|---|---|---|
| Price | $36.39 | $7.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $44.29 | $10.87 |
| AVG Volume (30 Days) | ★ 1.5M | 414.0K |
| Earning Date | 10-29-2026 | 07-28-2022 |
| Dividend Yield | ★ 1.87% | 1.18% |
| EPS Growth | ★ 15.05 | N/A |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $5,767,000,000.00 | N/A |
| Revenue This Year | $3.47 | $2.15 |
| Revenue Next Year | $5.71 | $6.22 |
| P/E Ratio | $22.70 | ★ $18.67 |
| Revenue Growth | ★ 2.27 | N/A |
| 52 Week Low | $29.94 | $6.96 |
| 52 Week High | $45.37 | $9.90 |
Technical Indicators
Market Signals| Indicator | KBR | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 56.79 | 53.50 |
| Support Level | $35.91 | $7.44 |
| Resistance Level | $36.49 | $7.65 |
| Average True Range (ATR) | 0.94 | 0.14 |
| MACD | 0.21 | 0.02 |
| Stochastic Oscillator | 96.09 | 91.57 |
Price Performance
Historical ComparisonAbout KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 36,000 people. The firm generated $7.8 billion in revenue in 2025.
About GRFS Grifols S.A.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.